315 Herpes simplex and eczema herpeticum in moderate to severe atopic dermatitis treated with abrocitinib

Abstract

Patients with atopic dermatitis (AD) have increased risk of herpes simplex (HS) infection. Eczema herpeticum (EH) is a serious complication of HS. In a published safety analysis of abrocitinib, HS was reported in 5.9% (116; IR 11.83) and 6.1% (54; IR 8.73) and EH was reported in 0.4% (8; IR 0.78) and 1.7% (15; IR 2.34) of patients treated with abrocitinib 200 mg (N=1971) and 100 mg (N=885), respectively. Two EH events occurred in patients with IGA score <2 (both 100 mg). This post hoc analysis further characterized HS and EH in the above analysis of pooled data from patients with moderate to severe AD receiving abrocitinib 200 mg or 100 mg in the phase 2b (NCT02780167) and phase 3 JADE MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), REGIMEN open-label induction phase (NCT03627767), and EXTEND long-term extension (NCT03422822) trials (data cutoff: April 22, 2020).